PLUS LAMIVUDINE;
NAIVE ADULTS;
RALTEGRAVIR;
ELVITEGRAVIR;
ADHERENCE;
THERAPY;
D O I:
10.1007/s40265-019-01247-1
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
The oral once-daily, fixed-dose single-tablet regimen (STR) of dolutegravir/lamivudine (Dovato (R)), combining a second generation integrase single-strand transfer inhibitor (INSTI) and a nucleoside reverse transcriptase inhibitor (NRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (> 12 years of age weighing at least 40 kg) with no known or suspected resistance to the INSTI class or lamivudine. In GEMINI trials in antiretroviral therapy (ART)-naive HIV-1-infected adults, treatment with dolutegravir plus lamivudine provided rapid and sustained virological suppression and was noninferior to dolutegravir plus tenofovir disoproxil fumarate/emtricitabine at 48 weeks, irrespective of baseline patient or disease characteristics. Virological suppression was sustained at 96 weeks in these ongoing trials. In patients with HIV-1 with sustained virological suppression on their current tenofovir alafenamide (AF)-based ART regimen (>= 3 drugs), switching to treatment with dolutegravir/lamivudine was noninferior to continuing on a tenofovir AF-based regimen at 48 weeks in the ongoing TANGO trial. No resistance mutations to dolutegravir or lamivudine were detected in patients who met criteria for confirmed virological withdrawal in GEMINI and TANGO trials. Hence, the dolutegravir/lamivudine STR is an effective, generally well tolerated and convenient initial and subsequent ART option for adolescents and adults with HIV-1 infection with no known or suspected resistance to the INSTI class or lamivudine.
机构:
Unit of Antiviral Therapy, Division of Infectious Diseases, AO Papa Giovanni XXIII, BergamoUnit of Antiviral Therapy, Division of Infectious Diseases, AO Papa Giovanni XXIII, Bergamo
Astuti N.
Maggiolo F.
论文数: 0引用数: 0
h-index: 0
机构:
Unit of Antiviral Therapy, Division of Infectious Diseases, AO Papa Giovanni XXIII, BergamoUnit of Antiviral Therapy, Division of Infectious Diseases, AO Papa Giovanni XXIII, Bergamo
机构:
Hop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
Univ Paris 07, Sorbonne Paris Cite, Paris, France
INSERM, U941, Paris, FranceHop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
Gallien, Sebastien
Flandre, Philippe
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris 06, Univ Sorbonne, INSERM, UMR S 1136,Pierre Louis Inst Epidemiol & Publ Hlt, Paris, FranceHop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
Flandre, Philippe
Nga Nguyen
论文数: 0引用数: 0
h-index: 0
机构:
Hop St Louis, APHP, Virol Lab, F-75010 Paris, FranceHop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
Nga Nguyen
De Castro, Nathalie
论文数: 0引用数: 0
h-index: 0
机构:
Hop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, FranceHop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
De Castro, Nathalie
Molina, Jean-Michel
论文数: 0引用数: 0
h-index: 0
机构:
Hop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
Univ Paris 07, Sorbonne Paris Cite, Paris, France
INSERM, U941, Paris, FranceHop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France
Molina, Jean-Michel
Delaugerre, Constance
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris 07, Sorbonne Paris Cite, Paris, France
INSERM, U941, Paris, France
Hop St Louis, APHP, Virol Lab, F-75010 Paris, FranceHop St Louis, APHP, Dept Infect Dis & Trop Med, F-75010 Paris, France